Context Therapeutics (CNTX) Institutional Ownership $0.69 -0.01 (-1.77%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.07 (+9.40%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Context Therapeutics (NASDAQ:CNTX)CurrentInstitutional OwnershipPercentage14.03%Number ofInstitutional Buyers(last 12 months)22TotalInstitutional Inflows(last 12 months)$63.11MNumber ofInstitutional Sellers(last 12 months)8TotalInstitutional Outflows(last 12 months)$3.65M Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CNTX Institutional Buying and Selling by Quarter Context Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025 Ally Bridge Group NY LLC1,157,448$708K0.6%-26.6%1.290% 5/15/2025 Landscape Capital Management L.L.C.41,216$25K0.0%-54.2%0.046% 5/14/2025 Affinity Asset Advisors LLC660,589$404K0.0%-34.9%0.736% 2/17/2025 Velan Capital Investment Management LP90,000$94K0.1%-93.0%0.120% 2/17/2025 Shay Capital LLC50,000$52K0.0%N/A0.067% 2/17/2025 MPM Bioimpact LLC14,705,882$15.44M2.2%N/A19.608% 2/17/2025 Millennium Management LLC178,718$188K0.0%+24.2%0.238% 2/17/2025 Citadel Advisors LLC29,900$31K0.0%N/A0.040% 2/17/2025 Allostery Investments LP950,166$998K1.0%N/A1.267% 2/17/2025 Ally Bridge Group NY LLC1,576,762$1.66M1.4%-10.3%2.102% Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/14/2025 Jane Street Group LLC27,395$29K0.0%N/A0.037% 2/14/2025 Northern Trust Corp113,565$119K0.0%-34.2%0.151% 2/14/2025 Blue Owl Capital Holdings LP6,357,928$6.68M1.6%+17.5%8.477% 2/13/2025 Marshall Wace LLP203,286$213K0.0%N/A0.271% 2/13/2025 Affinity Asset Advisors LLC1,015,340$1.07M0.1%-23.1%1.354% 2/13/2025 Walleye Capital LLC166,306$175K0.0%+51.7%0.222% 2/13/2025 Renaissance Technologies LLC338,435$355K0.0%+412.8%0.451% 2/13/2025 ADAR1 Capital Management LLC351,094$369K0.1%-6.1%0.468% 2/12/2025 Landscape Capital Management L.L.C.90,000$94K0.0%N/A0.120% 2/12/2025 Geode Capital Management LLC628,729$661K0.0%+9.2%0.838% 2/12/2025 Franklin Resources Inc.4,003,380$4.20M0.0%+115.9%5.338% 1/17/2025 Clear Harbor Asset Management LLC57,804$61K0.0%+60.6%0.077% 11/27/2024 Franklin Resources Inc.1,853,988$3.69M0.0%N/A2.472% 11/16/2024 Geode Capital Management LLC575,899$1.13M0.0%-6.8%0.768% 11/15/2024 Y Intercept Hong Kong Ltd45,635$89K0.0%N/A0.061% 11/15/2024 State Street Corp111,907$219K0.0%+21.5%0.149% 11/14/2024 Ally Bridge Group NY LLC1,757,524$3.45M1.8%-6.8%2.343% 11/13/2024 Great Point Partners LLC6,934,982$13.59M4.0%-6.5%9.247% 8/20/2024 Nantahala Capital Management LLC1,935,484$3.88M0.2%N/A2.581% 8/16/2024 Driehaus Capital Management LLC2,258,065$4.53M0.0%N/A3.011% 8/15/2024 Blue Owl Capital Holdings LP5,161,290$10.35M2.9%N/A6.882% 8/15/2024 Affinity Asset Advisors LLC1,619,140$3.25M0.4%+392.4%2.159% 8/14/2024 Great Point Partners LLC7,419,355$14.88M2.8%N/A9.893% 8/14/2024 Ally Bridge Group NY LLC1,886,232$3.78M2.3%+159.8%2.515% 8/9/2024 Renaissance Technologies LLC65,200$131K0.0%+63.4%0.087% 5/29/2024 Opaleye Management Inc.1,108,357$1.53M0.3%+13.7%1.478% 2/15/2024 Opaleye Management Inc.975,000$1.10M0.3%N/A6.107% 11/15/2023 Affinity Asset Advisors LLC328,817$497K0.1%+22.9%2.059% 8/21/2023 Affinity Asset Advisors LLC267,574$428K0.1%N/A1.675% 7/21/2023 Clear Harbor Asset Management LLC36,000$58K0.0%N/A0.225% Washington Is Broke—and Eyeing Your Savings Next (Ad)Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.Get your free guide now by clicking here >>2/16/2023 AIGH Capital Management LLC1,143,745$745K0.2%-11.5%7.162% 2/14/2023swisspartners Ltd.180,000$119K0.2%+111.8%1.127% 11/14/2022 Worth Venture Partners LLC322,628$358K0.2%+8.4%2.021% 11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532% 8/13/2022 Virtu Financial LLC46,445$98K0.0%N/A0.291% 8/12/2022 Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535% 5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090% 2/14/2022 Altium Capital Management LP493,531$1.31M0.4%N/A4.501% 2/11/2022QCM Cayman Ltd.14,041$37K0.2%N/A0.128% 2/10/2022 AIGH Capital Management LLC762,721$2.03M0.6%N/A6.955% 2/9/2022swisspartners Ltd.42,235$114K0.1%N/A0.385% (Data available from 1/1/2016 forward) CNTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CNTX shares? During the previous two years, 25 institutional investors and hedge funds held shares of Context Therapeutics. The most heavily invested institutionals were MPM Bioimpact LLC ($15.44M), Great Point Partners LLC ($13.59M), Blue Owl Capital Holdings LP ($6.68M), Driehaus Capital Management LLC ($4.53M), Franklin Resources Inc. ($4.20M), Nantahala Capital Management LLC ($3.88M), and Opaleye Management Inc. ($1.53M).Learn more on CNTX's institutional investors. What percentage of Context Therapeutics stock is owned by institutional investors? 14.03% of Context Therapeutics stock is owned by institutional investors. Learn more on CNTX's institutional investor holdings. Which institutional investors have been buying Context Therapeutics stock? Of the 22 institutional investors that purchased Context Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: MPM Bioimpact LLC ($14.71M), Great Point Partners LLC ($7.42M), Blue Owl Capital Holdings LP ($6.11M), Franklin Resources Inc. ($4.00M), Driehaus Capital Management LLC ($2.26M), Nantahala Capital Management LLC ($1.94M), and Affinity Asset Advisors LLC ($1.62M). How much institutional buying is happening at Context Therapeutics? Institutional investors have bought a total of 42,233,909 shares in the last 24 months. This purchase volume represents approximately $64.79M in transactions. Which Context Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Context Therapeutics stock in the last 24 months: Velan Capital Investment Management LP ($1.20M), Ally Bridge Group NY LLC ($728.78K), Affinity Asset Advisors LLC ($660.56K), Great Point Partners LLC ($484.37K), Northern Trust Corp ($58.95K), Landscape Capital Management L.L.C. ($48.78K), and Geode Capital Management LLC ($42.28K). How much institutional selling is happening at Context Therapeutics? Institutional investors have sold a total of 3,246,790 shares in the last 24 months. This volume of shares sold represents approximately $3.65M in transactions. Related Companies CMPX Major Shareholders DBVT Major Shareholders CRVS Major Shareholders RNAC Major Shareholders IMMP Major Shareholders AURA Major Shareholders CGC Major Shareholders TSVT Major Shareholders ITOS Major Shareholders TERN Major Shareholders This page (NASDAQ:CNTX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTX Stock Free CNTX Stock Alerts